UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2577-2584

2021

Link zum Volltext

Verfügbarkeit prüfen

Second Malignancies Among Elderly Survivors of Cancer

The oncologist (Dayton, Ohio), 2011-11, Vol.16 (11), p.1572-1581

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

Frontiers in oncology, 2023-08, Vol.13, p.1215524-1215524

2023

Link zum Volltext

Verfügbarkeit prüfen

Detection of NRG1 Gene Fusions in Solid Tumors

Clinical cancer research, 2019-08, Vol.25 (16), p.4966-4972

2019

Link zum Volltext

Verfügbarkeit prüfen

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

NPJ precision oncology, 2023-11, Vol.7 (1), p.120-120, Article 120

2023

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events

Clinical lung cancer, 2022-12, Vol.23 (8), p.686-693

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Functional Characterization of Atypical KRAS / NRAS Mutations in Metastatic Colorectal Cancer

Clinical cancer research, 2021-08, Vol.27 (16), p.4587-4598

2021

Link zum Volltext

Verfügbarkeit prüfen

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Molecular cancer therapeutics, 2021-01, Vol.20 (1), p.183-190

2021

Link zum Volltext

Verfügbarkeit prüfen

Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers

Molecular cancer therapeutics, 2022-01, Vol.21 (1), p.227-236

2022

Link zum Volltext

Verfügbarkeit prüfen

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.676-676

2017

Link zum Volltext

Verfügbarkeit prüfen

705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A800-A800

2023

Link zum Volltext

Verfügbarkeit prüfen

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

Journal of clinical oncology, 2013-06, Vol.31 (18_suppl), p.LBA9008-LBA9008

2013

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Link zum Volltext

Verfügbarkeit prüfen

The safety and efficacy of immune checkpoint inhibitor rechallenge after immune-related adverse events in stage IV NSCLC patients

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21173-e21173

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9039-9039

2023

Link zum Volltext

Verfügbarkeit prüfen

Racial disparities in performance status among cancer patients at a community oncology practice

Journal of clinical oncology, 2020-10, Vol.38 (29_suppl), p.132-132

2020

Link zum Volltext

Verfügbarkeit prüfen

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18048-e18048

2023

Link zum Volltext

Verfügbarkeit prüfen

Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9069-9069

2023

Link zum Volltext

Verfügbarkeit prüfen

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2612-2612

2023

Link zum Volltext

Verfügbarkeit prüfen

Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9120-9120

2023

Link zum Volltext

Verfügbarkeit prüfen

Characterizing non-small cell lung cancer driven by mutations in ARAF and CRAF family members

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15085-e15085

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular characterization of nectin-4 in non-small cell lung cancer subtypes

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21119-e21119

2023

Link zum Volltext

Verfügbarkeit prüfen

Liver abscess as a complication of hepatic transarterial chemoembolization: a case report, literature review, and clinical recommendations

Gastrointestinal cancer research, 2009-11, Vol.3 (6), p.247-251

2009

Link zum Volltext

Verfügbarkeit prüfen

Pan-cancer analysis of YAP1 expression as a predictive biomarker for cancer immunotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2629-2629

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular characterization of NF1-mutated NSCLC and clinical outcomes

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9086-9086

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(102)
Berichte
(1)

Sprache

Englisch
(103)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Oncology
(21)
Humans
(18)
Aged
(10)
Female
(9)
Male
(8)
Middle Aged
(8)
Adult
(6)
Melanoma
(6)
Cancer Research
(5)
Metastasis
(5)
Mutation
(5)
Patients
(5)
Chemotherapy
(4)
Immunotherapy
(4)
Tumors
(4)
Adolescent
(3)
Aged, 80 And Over
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Second Malignancies Among Elderly Survivors of Cancer

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

Detection of NRG1 Gene Fusions in Solid Tumors

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events

Clinical and Functional Characterization of Atypical KRAS / NRAS Mutations in Metastatic Colorectal Cancer

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway

705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The safety and efficacy of immune checkpoint inhibitor rechallenge after immune-related adverse events in stage IV NSCLC patients

Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC

Racial disparities in performance status among cancer patients at a community oncology practice

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck

Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR)

Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)

Characterizing non-small cell lung cancer driven by mutations in ARAF and CRAF family members

Molecular characterization of nectin-4 in non-small cell lung cancer subtypes

Liver abscess as a complication of hepatic transarterial chemoembolization: a case report, literature review, and clinical recommendations

Pan-cancer analysis of YAP1 expression as a predictive biomarker for cancer immunotherapy

Molecular characterization of NF1-mutated NSCLC and clinical outcomes

Suchergebnisse filtern